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Abstract: C/EBPβ is a leucine-zipper transcription factor implicated in the control of metabolism, 
development, cell differentiation, and proliferation. However, it remains unclear its role in tumor 
development. Here, we show that down regulation of C/EBPβ by RNA interference inhibits 
proliferation in the GL261 murine glioblastoma cell line, induces an arrest of the cell cycle at the G0/G1 
boundary, and diminishes their transformation capacity and migration. In addition, we show that 
C/EBPβ regulates the expression of several DNA damage response- and invasion-related genes. Lastly, 
C/EBPβ depletion significantly retards tumor onset and prolongs survival in a murine orthotopic brain 
tumor model. Immunohistochemical analysis revealed a significant diminution of PCNA labeling in 
tumors derived from C/EBPβ-depleted GL261 cells compared with that in controls. These results show, 
for the first time, the dependence of glioma cells on C/EBPβ and suggest a potential role of this 
transcription factor in glioma development. 
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revised manuscript we have also added the phrases “Interestingly we also found 
four genes, Mcam1, Plaur, integrin beta 3 and vascular endothelial growth factor C, 
which have been implicated in promoting angiogenesis” (page 12, lines 14-16) and 
“The reduced vascularisation observed in those mice implanted with C/EBP 
knockdown cells, could be due, al least in part, to the down-regulation by this 
transcription factor of several genes involved in the promotion of angiogenesis” 
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ABSTRACT 
 
C/EBP is a leucine-zipper transcription factor implicated in the control of metabolism, 
development, cell differentiation, and proliferation. However, it remains unclear its role 
in tumor development. Here, we show that down regulation of C/EBP by RNA 
interference inhibits proliferation in the GL261 murine glioblastoma cell line, induces 
an arrest of the cell cycle at the G0/G1 boundary, and diminishes their transformation 
capacity and migration. In addition, we show that C/EBPβ regulates the expression of 
several DNA damage response- and invasion-related genes. Lastly, C/EBP depletion 
significantly retards tumor onset and prolongs survival in a murine orthotopic brain 
tumor model. Immunohistochemical analysis revealed a significant diminution of 
PCNA labeling in tumors derived from C/EBP-depleted GL261 cells compared with 
that in controls. These results show, for the first time, the dependence of glioma cells on 
C/EBP and suggest a potential role of this transcription factor in glioma development. 
 
 
Keywords: C/EBP, glioblastoma, invasion, proliferation, shRNA. 
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INTRODUCTION 
 
The CCAAT/Enhancer binding protein  (C/EBP) is a basic leucine zipper 
transcription factor (Vinson et al., 1989) involved in different cell processes including 
metabolism, hematopoiesis, adipogenesis, the immune response, and morphogenesis 
(Poli, 1998, Ramji and Foka, 2002). C/EBP is also expressed in the central nervous 
system (Sterneck and Johnson, 1998, Nadeau et al., 2005) where it plays an important 
role in the consolidation of long-term memory (Alberini et al., 1994, Taubenfeld et al., 
2001), and cortical neuronal maturation (Menard et al., 2002). We have demonstrated 
that C/EBP is an important factor in neuronal differentiation (Cortes-Canteli et al., 
2002) and regulates the expression of several genes involved in inflammatory processes, 
cancer, and brain injury (Cortes-Canteli et al., 2004). More importantly, mice lacking 
C/EBP show a reduced inflammatory response after an excitotoxic insult and are less 
susceptible to neuronal cell loss (Cortes-Canteli et al., 2008). 
 
Regarding its implication in proliferation and differentiation processes, different roles 
have been proposed for C/EBP. An antiproliferative function has been suggested in 
HepG2 hepatocarcinoma cells (Buck et al., 1994), epidermal keratinocytes (Zhu et al., 
1999) and primary fibroblasts (Sebastian et al., 2005). Moreover, C/EBP-knockout 
mice display a lymphoproliferative disorder, suggesting that C/EBP inhibits expansion 
of the lymphoid cell compartment (Screpanti et al., 1995). However, growth arrest 
induced by C/EBP appears to be highly context specific, because in several cases 
C/EBP displays potent growth-promoting activity. C/EBP is highly expressed in 
colorectal tumors (Rask et al., 2000) and is associated with ovarian tumor progression 
(Sundfeldt et al., 1999). Ectopic expression of C/EBP induces proliferation in human 
mammary epithelial cells (Bundy and Sealy, 2003) and macrophage tumor cells 
(Wessells et al., 2004). Also, C/EBP-/- mice show impaired mammary ductal 
morphogenesis due to a proliferation defect (Robinson et al., 1998, Seagroves et al., 
1998) and are totally resistant to carcinogen-induced skin tumor development (Zhu et 
al., 2002). 
 
High-grade gliomas, which include glioblastoma (GBM) and anaplastic astrocytoma, 
are among the most common intrinsic brain tumors in adults and are nearly uniformly 
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fatal (DeAngelis, 2001). Despite significant improvements in the early detection of 
malignant gliomas, the median survival of patients remains less than 12 months from 
the time of diagnosis (Benedetti et al., 2000, DeAngelis, 2001). Advances in glioma 
modeling in the mouse have made the disease amenable to in vivo functional and 
molecular studies (Fomchenko and Holland, 2006). However, the mechanisms 
underlying GBM pathogenesis and poor response to conventional therapy are yet 
unclear. Interestingly, it has been recently demonstrated that C/EBP expression is 
markedly increased in high-grade glioma compared with low-grade glioma, and low 
expression in tumor tissue correlates with longer patient survival (Homma et al., 2006). 
 
All these data has prompted us to investigate whether C/EBP is involved in 
glioblastoma development. Here, we present evidence that C/EBP is strongly 
expressed in glioma cells. Furthermore, reduction of C/EBP levels inhibits 
glioblastoma cell growth in vitro and in vivo. The demonstration that C/EBP is a 
critical positive regulator of glioma growth will provide new targets for the 
development of future brain tumor treatments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                
 
 
5 
MATERIALS AND METHODS 
 
Construction of small interfering RNAs and Stable transfection 
GL261 murine glioblastoma cells were obtained from the NCI-Frederick Cancer 
Research Tumor Repository (Frederick, MD) and propagated in RPMI medium with 10 
% fetal bovine serum as described (El Andaloussi et al., 2006). To knockdown C/EBP 
expression, siRNA against two different target sites of mouse C/EBP and a non-
targeting siRNA control were obtained from Dharmacon (Thermo Scientific, Waltham, 
MA). The interfering selected sequences were 5‟-GAG CGA CGA GTA CAA GAT G-
3‟ (pool I4) and 5‟ –CCT TTA GAC CCA TGG AAG TTT- 3‟ (pool I5). The 
oligonucleotides were annealed and the double-stranded oligonucleotides were cloned 
into pSilencer 4.1 vector (Ambion, Austin, TX), in which shRNAs were expressed 
under the control of the CMV promoter. The plasmids were transfected into GL261 
glioblastoma cells by using Lipofectamin 2000 (Invitrogen, CA) and stable transfectans 
were selected using 400 g/ml of G418 and maintained in this selection medium. Pools 
C1 (expressing a non-targeting shRNA control) and I4 (expressing a shRNA against 
C/EBP) were used throughout the study. LN18 human glioblastoma cells were 
obtained from Dr. Peinado (Department of Cell and Developmental Biology, Cornell 
University) and maintained in DMEM medium with 10% fetal bovine serum, 2mM 
Glutamine, 100µg/ml penicillin and 100µg/ml streptomycin. Human C/EBP 
expression was silenced in LN18 cells using the FUGW lentiviral vector. The 
interfering selected sequence was: 5′- GAA GAC CGT GGA CAA GCA C -3′ (pool 
FC1). A non-targeting sequence (5′- GCC GCT TTG TAG GAT AGA G -3′, pool FS) 
was also used. These lentiviral vectors were obtained from Dr. Quintanilla-Martinez. 
For lentiviral infections of LN18 cells, 293T cells were transiently transfected with the 
appropriate lentiviral expression vector and the vectors pMD2-G, pMDLg/pRRE, and 
pRSV-Rev, which encode lentiviral proteins. The medium containing lentiviruses was 
recovered, filtered through a 0.45-μm filter and added to the recipient cells. The same 
procedure was repeated 8 h and 24 h later. Pools FS (expressing a non targeting 
shRNA) and FC1 (expressing a shRNA against C/EBPβ) were used in this study. 
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Immunoblot analysis 
Cultured cells were harvested and lysed in ice-cold RIPA buffer and equal quantities of 
total protein were separated by 12 % SDS-PAGE. After electrophoresis, proteins were 
transferred to nitrocellulose membranes (Protran, Whatman, Dassel, Germany) and blots 
were probed with the indicated primary antibodies, as previously described (Cortes-
Canteli et al., 2004). The antibodies used were the following: goat polyclonal C/EBP, 
rabbit polyclonal anti-C/EBP, rabbit polyclonal anti-C/EBP rabbit polyclonal anti-
Brca1, rabbit polyclonal anti-p27 (Santa Cruz Biotechnology, CA, U.S.A.), mouse 
monoclonal anti--tubulin (Sigma), mouse monoclonal anti-ATM (Novus Biologicals, 
Littleton, CO, U.S.A.) and mouse monoclonal anti-Chk2 (Millipore, Billerica, MA, 
U.S.A.) antibodies. Secondary peroxidase-conjugated donkey anti-rabbit and rabbit 
anti-mouse antibodies were from Amersham Biosciences (GE Healthcare, 
Buckinghamshire, England) and Jackson Immunoresearch, respectively.  
 
Proliferation assays and cell cycle studies 
 The effect of C/EBP expression on cell proliferation was determined using the non-
radioactive BrdU-based cell proliferation assay (Roche) according to the manufacturer‟s 
protocol. Cells were seeded in triplicate onto 96-well plates at a density of 2,000 
cells/well. After 24 h of growth, 10 M BrdU was added and cells were cultured for 
another 16 h. BrdU incorporation into the DNA was determined by measuring the 
absorbance at both 450 and 690 nm on an ELISA plate reader. BrdU incorporation was 
also analyzed by immunofluorescence analysis, and the number of stained cells was 
counted using the Image J program. 
Cell viability was measured using the MTT assay (Roche Diagnostic, GmbH), based on 
the ability of viable cells to reduce yellow MTT to blue formazan. Briefly, cells were 
cultured in 96-well microtitre plates for various periods of time, then cells were 
incubated with MTT (0.5 mg/ml, 4h) and subsequently solubilized in 10 % SDS/0.01 M 
HCl for 12 h in the dark. The extent of reduction of MTT was quantified by absorbance 
measurement at 550 nm according to the manufacturer‟s protocol. 
For analysis of progression through the cell cycle cells were fixed in 70% ethanol/PBS, 
pelleted and resuspended in buffer containing 10 g/ml RNAse and 0.003 % propidium 
iodide, as previously described (Pignatelli et al., 2001). Cell cycle distribution was 
determined by flow cytometric analysis utilizing a Cyan MLE-R Cytometer (DAKO-
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Cytomation, Glastrup, Denmark). Data analysis was performed using the Summit 
Software (DAKO). 
 
Soft agar colony formation assay 
To perform anchorage-independent growth assays, 50,000 cells were resuspended in 1 
ml of 0.7% agar in tissue culture medium containing 10% serum in 60 mm plates over a 
bottom layer of 1 % agar in medium. The cells were allowed to grow for 21 days with 
weekly refeeding. Colonies were stained with p-iodotetrazolium violet and 20 randomly 
selected fields were photographed under a phase-contrast microscope (10x 
magnification). Colonies were then counted, and the mean number of colonies per plate 
was calculated. All experiments were done in triplicate. 
 
Cell invasion, migration and wound healing assay 
 Tumor cell invasion assays were performed using Transwell chambers with 12-m 
pores (Costar) coated with a layer of Matrigel free of growth factors (Collaborative 
Biomedical). Medium with 20 % fetal bovine serum was added to the lower chambers 
of the Transwells. I4 or C1 cells (50,000) were seeded on top of the Transwell in 
triplicate in medium without serum and incubated at 37º for 48 h. The bottom filters 
were fixed and stained with DAPI at the end of the experiments. Cells in the top 
chambers were removed by wiping with cotton swabs, and the stained cells that had 
migrated through the Matrigel were counted under a microscope. Ten randomly selected 
20x microscopic fields were counted. Wound healing assay was used to detect the 
alteration of cell motility. I4, C1, FS and FC1 cells were seeded onto 60-mm plates and, 
after overnight incubation, an artificial wound was created using P200 pipette tip to 
scratch on the confluent cell monolayer. Photomicrograph was taken immediately (time 
0 h), so that the migrating cells and closing of scratch wound could be observed. 
Microphotograhs were also taken at 24 and 48 h post wounding. Within each assay the 
experiments were performed in triplicates. 
 
PCR-Array  
Total RNA was extracted from C1 and I4 pools by using TRIzol (Invitrogen, Carlsbad, 
CA). Genomic DNA contamination was eliminated by Dnase treatment and C/EBP 
expression was tested by PCR before starting PCR-Array procedure. Mouse Cancer and 
Cell Cycle RT Profiler PCR Arrays were purchased from SuperArray Bioscience 
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Corporation (Frederick, MD). PCR was performed on ABI Prism 7700 Sequence 
Detector (Applied Biosystems). Data were analyzed using the DDCt method and the 
housekeeping genes HPRT1, GAPDH, and -actin for normalization. For each gene 
fold-changes were calculated as difference in gene expression between C1 and I4 pools. 
 
Animal Experiments 
Adult male C57BL/6 mice (n ≥ 7 per group) were anaesthetized by intraperitoneal 
injection of ketamine (60 mg/Kg) and medetomidine (0.125 mg/Kg) and positioned in a 
stereotaxic apparatus (Kopf Instruments, CA). To establish intracranial tumors I4 or C1 
cells (100,000 cells) were implanted unilaterally into the left hemisphere using the 
following coordinates from Bregma: posterior -1.06 mm; lateral -3 mm and a depth of 3 
mm, according to the atlas of Paxinos and Franklin (Paxinos and Franklin, 2001). The 
mice were then housed individually to recover. All procedures with animals were 
carried out in accordance with the protocols issued by the „Ethics Committee for 
Animal Experimentation‟ of the Instituto de Investigacones Biomédicas (CSIC-UAM), 
which followed National (normative 1201/2005) and International recommendations 
(normative 86/609 from the European Communities Council). Special care was taken to 
minimize animal suffering. 
 
Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) was performed using an MRI scanner (Bruker 
PharmaScan 7.0T, 16 cm; Bruker Medical Gmbh, Ettlingen, Germany). Mice brain MRI 
was performed with a 90 mm gradient insert and a concentrical 38 mm birdcage 
resonator, using Paravision v4.0 software (Bruker Medical Gmbh, Ettlingen, Germany) 
as implemented in a Hewlett-Packard console, operating on a Linux platform. MRI 
examinations used adult male C57BL/6 mice (n ≥ 7 per group) anaesthetized through a 
plastic mask with 2% isofluorane in 99.9% O2. Animals were allowed to breath 
spontaneously during the experiment and were placed in a heated cradle to maintain the 
core body temperature at approx. 37 ºC. The physiological state of the animal was 
monitored throughout MRI acquisition through the respiratory rate using a Biotrig 
physiological monitor (Brucker). Gadolinium-DTPA-enhanced T1-weighted spin-echo 
images were acquired at 11, 15, and 18 days after injection with a Rapid Acquisition 
with Relaxation Enhancement (RARE) (Hennig et al., 1986) sequence in axial 
orientations (TR: 350 ms, TE: 10.6 ms, averages: 4, FOV: 2.30 cm, acquisition matrix: 
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256×256, slice thickness: 1.00 mm, number of slices: 16). The in vivo spectroscopy 
protocol acquired two 3x3x3 mm voxels in the striatal area, using a Point-Resolved 
Spatially Spectroscopy (PRESS)
 
(Bottomley, 1987) protocol, combined with VAPOR 
water suppression, (Tkac et al., 1999)(TR: 3000 ms, TE: 35 ms, averages: 128). The 
tumor area was calculated from T1-weighted images using image J analysis software. 
Tumor volume was estimated from the summation of tumor areas on each slice, 
multiplied by slice thickness.  
 
Histology and Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections (4 m) from tumors were deparaffinized in 
xylene, rehydrated in a graded series of alcohols, and rinsed in distilled water. All 
immunohistochemistry analysis were performed as previously described (Luna-Medina 
et al., 2007). The proliferative activity of the tumor was assessed with anti-PCNA 
antibody.  
 
Statistics 
 Other than the survival experiments, Student‟s test was used to analyze statistical 
differences between the different groups. Survival curves were plotted with Kaplan-
Meier method and survival for the two groups of animals was studied using log-rank 
test. Differences were considered statistically significant at p < 0.05. 
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10 
RESULTS 
 
Effect of C/EBPdepletion on GL261 cell proliferation and viability.  
We first analyzed the basal level of expression of C/EBP in murine GL261 
glioblastoma cells. Our results showed increased C/EBP expression in contrast to 
primary astrocytes, and these levels were very similar to those present in 
lipopolisaccharide-activated astrocytes (Fig. 1A). To investigate the cellular action of 
the C/EBP protein in GL261 cells, we stably introduced a pSilencer vector encoding 
shRNA for C/EBP or non-targeting shRNA (see “Materials and Methods”), and 
different geneticin-resistant pools were tested for C/EBP expression using an antibody 
specific for C/EBP. We evaluated the efficacy of shRNA transfection in the silencing 
of gene expression of C/EBP by using Western blot analysis. The immunoblot in 
Figure 1B shows that in two of these interfered pools, I4 and I5, the content of C/EBP 
protein decreased approximately 75%, as compared to control C1 and C2 pools. For this 
reason we selected the I4 and C1 pools for subsequent studies. Figure 1C shows a 
dramatic decrease in the protein levels of C/EBP in the human LN18 cells expressing 
the shRNA for this mRNA (FC1) compared to control cells expressing a non-target 
sequence (FS). In order to confirm the specificity of the shRNA used and to 
demonstrate that does not interfere or modulate by compensatory effect the expression 
of other members of the C/EBP family, we performed Western Blot analysis to measure 
the protein levels of C/EBP and C/EBP, the other two members of the family which 
have been implicated in tumorigenesis. As can be observed in Figure 1D, neither of 
them were detected in GL261 cells. LN18 cells presented some expression of C/EBP 
and very little of C/EBP, though their expression was similar in the control and 
interfered pools. 
 
We next investigated whether glioma cell proliferation is directly affected by C/EBP. 
Although downregulation of C/EBP in glioma cells did not alter cell morphology (data 
not shown), proliferation, as measured by BrdU incorporation and subsequent ELISA 
analysis (Fig. 2A) was decreased to 50% in the I4 pool compared with control cells.  
These results were similar to those obtained with the I5 pool. This growth inhibitory 
effect was further confirmed by BrdU immunocytochemical analysis (Fig. 2B). 
Additionally, cell viability, measured by the MTT assay, was significantly diminished 
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11 
in the I4 pool, compared to its C1 control pool (Fig. 2C). This decrease in cell viability 
was also observed in the interfered human FC1 glioblastoma cells, compared to control 
FS cells. These data show that C/EBP plays a vital role in maintaining glioblastoma 
cell proliferation. To better understand the nature of the growth retardation associated 
with decreased expression of C/EBP, we next performed cell cycle analysis. The 
proportion of cells at specific stages of the cell cycle was determined by flow 
cytometry. It was observed (Fig. 2D) that the cell cycle profiles of I4 cells were 
significantly altered, with a block at the G0/G1 boundary, less cells progressing through 
the S-phase than the control C1 cells and a concomitant decline in the number of cells in 
G2/M phase. We also observed an increased in the sub-G0/G1 subpopulation suggesting 
an increase in the number of apoptotic cells in the pool I4 with lower expression of 
C/EBP. The ability of cancer cells to grow without adhering to extracellular matrix 
proteins (anchorage-independent growth) correlates closely with their ability to form 
malignant tumors. Anchorage-independent growth presumably allows the cells to 
invade and metastasize, characteristics that distinguish malignant from benign tumors. 
Thus, to assess the effect of C/EBP expression on anchorage-independent growth of 
GL261 cells, we seeded C1 and I4 cells in medium containing 0.7 % agar, and counted 
colonies 21 days later. As shown in Figure 2E, we observed a significant reduction in 
the number of the colonies of C/EBP knock down cells compared with control-
transfected cells (45±7 and 120±9 colonies/plate, respectively; ***p0.001). Hence, 
depletion of C/EBP expression partially inhibited the anchorage-independent growth 
of GL261   cells.  
 
C/EBP depletion inhibits glioblastoma motility and invasion.  
The ability of glioblastoma cells to invade into normal surrounding tissue is influenced 
by their motility as well as ability to penetrate through tissue barriers such as 
extracellular matrix. To assess the role of C/EBP in glioblastoma cell motility, we used 
“scratch-wound” assays. These assays showed that both murine GL261 cells and human 
LN18 cells depleted of C/EBP did not fill in a scratch as rapidly as cells treated with a 
control RNA duplex, suggesting decreased cell motility (Fig. 3A). To further 
substantiate these findings, we also assessed glioblastoma cell motility using Transwell 
chambers. In these assays, control cells and cells depleted of C/EBP are replated into 
Transwell chamber membranes coated with Matrigel at the same density and 48 h later 
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12 
the numbers of cells that have crossed the chamber membrane are counted. Depletion of 
C/EBP in GL261 cells  (I4 and I5 pools) resulted in a significant decrease in the 
number of cells that crossed the Matrigel-coated membranes, indicating a true decrease 
in motility and invasive ability (Fig. 3B).  
 
To further analyze the mechanism involved in the stimulatory effect of C/EBP on 
GL261 glioblastoma cells, we studied the expression of genes implicated in these 
processes. To this end we screened two arrays of cell cycle and cancer-related genes. As 
shown in Table I, among other, we found a number of genes involved in the DNA 
damage response, such as ATM, Brca1, Brca2, Chk1, Chk2, and p27, that were 
significantly up-regulated in the I4 C/EBP-deficient cells (Table I). In contrast, we 
found that the expression of a substantial number of genes involved in adhesion 
invasion, and metastasis, including integrin 3, melanoma cell adhesion molecule, 
plasminogen activation urokinase receptor, and S100 calcium binding protein A4, was 
down-regulated in I4 cells. Interestingly we also found four genes, Mcam1, Plaur, 
integrin beta 3 and vascular endothelial growth factor C, which have been implicated in 
promoting angiogenesis. We next assessed these C/EBP-induced changes of the 
expression of the genes involved in the DNA damage response at the protein level. We 
found that, according with the PCR-array data, the abundance of all of them was 
significantly increased in the interfered lines (Fig. 4), suggesting that the observed 
effects of C/EBP interference could be mediated by it effects upon the G0/G1 
checkpoint, and an impairment in the progression through the cell cycle with a 
concomitant inhibition of glioblastoma progression. 
 
Knockdown of C/EBP inhibits the growth of GL261 glioma cells in vivo. Based on 
the above in vitro findings, C/EBP appears to be important in the growth of 
glioblastoma cells. To investigate whether the effects of C/EBP knockdown on 
glioblastoma growth inhibition are sustained in vivo, we next orthotopically implanted 
GL261 glioma cells into mice brains to generate tumors. The murine glioma GL261 
model has been the most common used syngeneic transplant model for both 
subcutaneous and intracranial experimental glioma tumors (Miyatake et al., 1997, 
Kjaergaard et al., 2000, Edwards et al., 2002). This particular intracranial animal model 
recapitulates many of the histopathological and biological features of human glioma 
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13 
including both necrosis with pseudopalisading and invasion of the brain adjacent to 
tumor as isolated single cells and as group of cells around vascular channels (Zagzag et 
al., 2003). To control for equal tumor loading, we monitored tumor growth in vivo by 
magnetic resonance imaging (MRI) at different times after implantation. Mice injected 
with C/EBP-deficient cells also showed a delayed onset and progression of tumors 
compared to C1 controls and tumor volume, as assessed by T1-weighed images after 
gadolinium contrast administration, revealed a significant reduction in tumor volume in 
mice implanted with C/EBP-deficient I4 cells (Fig. 5A, B). About 85% reduction in 
tumor volume was observed in I4-derived tumors at 15 days post-injection. This strong 
reduction in the tumor growth potential induced by C/EBP interference was 
maintained over time. Both the log-rank test and Kaplan-Meier analysis of the survival 
data demonstrated a significant survival advantage for the C/EBP low expression 
glioma-bearing mice when compared to their matched C/EBP high expression parental 
glioma-bearing animals (Fig. 5C). Log-rank analysis of the data yielded a p value of 
0.0012. Mice injected with I4 cells presented a significant increase in the mean survival 
(41 versus 26.5 days).  
 
Because the C/EBP-deficient tumors arose at a later time point, we anticipated that 
they would differ histologically and possibly also in terms of malignancy. Here, a 
difference between C1- and I4-derived tumors became apparent. Although both I4 and 
C1 pools gave rise to gliomas, which according to pathologists could be classified as 
grade IV glioblastoma, C/EBP-deficient tumors did not show blood vessels formation 
or multinucleated giant cells, typical features of aggressive grade IV glioblastomas (Fig. 
5D). Also, we did not detect necrosis areas in tumors derived from I4 cells, in 
comparison with C1-derived tumors, 18 days after injection. In addition, the PCNA 
labeling, a measure of proliferation, of I4-derived tumors, was significantly less than 
that of the C1 tumors (Fig. 5E), again suggesting a growth-suppressing action of 
C/EBP on tumor cells in vivo.  
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DISCUSSION 
 
Glioblastoma multiforme is the most common form of brain tumor occurring in adults. 
This devastating disease is usually incurable and patients have a mean survival time of 
approximately 1 year after diagnosis (Benedetti et al., 2000, DeAngelis, 2001). Here, we 
show that C/EBP has a role in promoting glioblastoma growth in vitro and in vivo. The 
C/EBP gene has been shown to promote both growth arrest and increased proliferation 
in a context-specific manner. How it stimulates mitotic growth and why it elicits 
completely opposite effects on proliferation in different cellular contexts remains to be 
ascertained. In this study, we show for the first time that depletion of C/EBP 
expression suppresses glioma cell growth in vitro and glioma tumor growth in vivo. 
This was accompanied by a regulation of the expression of different genes involved in 
DNA damage response and in invasion and metastasis. Collectively, our findings 
suggest that C/EBP might play an important role as a growth regulator in high-grade 
gliomas opening out a new role for C/EBP in the pathogenesis of central nervous 
system tumors.   
 
We have focused our work on the study of the oncogenic role of C/EBP in glioma. We 
have found that a high C/EBP level is a poor prognosis marker, supporting that 
C/EBP is acting as an oncogenic factor in glioblastomas and has an important role in 
their progression. Although C/EBP, another member of the C/EBP family, has 
emerged as a clear negative regulator of cell proliferation in many cellular contexts 
raising the possibility that could function as a tumor suppressor (Schuster and Porse, 
2006), the function of C/EBP upon proliferation, in situations where the function of 
C/EBP is straightforward, is more complex. Several data suggested that C/EBP might 
work as an anti-proliferative agent. C/EBP, similarly to C/EBP, is able to suppress 
cell proliferation through repression of E2F target-genes in a manner dependent on 
members of the retinoblastoma protein family (Sebastian et al., 2005). Also, C/EBP 
expression has been associated with growth arrest of keratinocytes (Zhu et al., 1999) 
and induction of cell cycle exit induced by Ras
V12
 in primary cells (Hanlon and Sealy, 
1999, Shuman et al., 2004). However, and in agreement with our results, other studies 
have suggested a growth-promoting activity for C/EBP. Zhu et al (Zhu et al., 2002) 
have shown that C/EBP-/- mice are completely refractory to skin tumorigenesis 
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15 
induced by the carcinogen 7,12-dimethyl-benz[a]anthracene, that produce oncogenic ras 
mutations in epidermal keratinocytes, suggesting an important role for C/EBP in 
keratinocytes survival in response to oncogenic ras and in skin tumorigenesis (Sterneck 
et al., 2006). C/EBP also functions as a survival factor in myc/ras transformed 
macrophages in vitro (Wessells et al., 2004) and in Wilms tumor cells (Li et al., 2005) 
and has been associated with ovarian tumor progression (Sundfeldt et al., 1999).  
 
Here, we show that C/EBP exerted a stimulatory effect on murine and human 
glioblastoma cell proliferation and viability in vitro. Inhibition of C/EBP expression 
leads to G1 arrest and reduced S phase in GL261 cells. These effects are accompanied 
by an increase in the expression of several genes involved in the DNA damage 
response, such as ATM, Brca1, Brca2, Chk1, Chk2, and p27, thereby ensuring a non-
proliferative outcome. These results provide support for the possibility that depletion of 
C/EBP inhibits cell proliferation and survival in glioblastoma cells by directly 
affecting the expression of these genes resulting in an activation of the G0/G1 
checkpoint, and impairment in the progression through the cell cycle and consequently 
an inhibition of glioblastoma progression in vivo. Consistent with this proposal, the 
regulatory regions of all these genes present consensus binding sites for C/EBP, 
suggesting that this protein can indeed directly regulate their expression. Also, and in 
agreement with our results, it has been shown that overexpression of C/EBP in a 
human mammary epithelial cell line leads to anchorage independent growth and 
invasive properties (Bundy and Sealy, 2003). We show here that a decrease in C/EBP 
expression leads to an inhibition of colony growth in soft agar, suggesting that C/EBP 
plays a role in the oncogenic process of anchorage-independence and is critical for 
tumor growth in glioblastoma. In this regard, results from the PCR array analysis also 
show that C/EBPdepletion decreases the mRNA levels of different genes involved in 
invasiveness and metastasis, including integrin 3, melanoma cell adhesion molecule, 
plasminogen activation urokinase receptor, and S100 calcium binding protein A4, 
suggesting that the induction of these genes by C/EBP could mediate its effects on 
these processes.  
 
Notably, it has recently been demonstrated that expression of C/EBP is markedly 
increased in high-grade glioma compared with low-grade glioma, and patients whose 
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16 
expression of C/EBP in tumor tissue was lower survived longer than those whose 
expression was higher (Homma et al., 2006). These results are consistent with our data 
showing that C/EBP knockdown inhibited glioblastoma tumor growth in vivo. 
Consequently, tumor development was significantly delayed in mice injected with I4 
cells. Our data clearly show that those mice bearing GL261 cells with high C/EBP 
expression had poorer survival than mice bearing C/EBP-deficient tumors (p = 
0.0012). Moreover, C/EBP-silenced glioblastoma lacked the aggressiveness of control 
tumors, including enhanced blood vessel formation and abundance of giant cells, 
suggesting that in addition to proliferation, C/EBP signaling is also an effective 
regulator of malignant transformation in glioblastoma cells in vivo. The reduced 
vascularisation observed in those mice implanted with C/EBP knockdown cells, could 
be due, al least in part, to the down-regulation by this transcription factor of several 
genes involved in the promotion of angiogenesis.  This lends support to the view that 
dysregulated C/EBP expression could influence glioblastoma development. Our results 
are supported by a recent paper demonstrating that expression of C/EBP is linked to 
the mesenchymal state of primary glioblastoma and provide an excellent prognostic 
biomarker for tumor aggressiveness (Carro et al.). 
 
In conclusion, our study demonstrates that C/EBP is a crucial regulator of 
glioblastoma cell growth and transformation and that several genes involved in DNA 
repair, invasion and metastasis may be important downstream effectors of C/EBP-
mediated oncogenic properties. These findings are clinically relevant because advanced-
stage glioblastomas are refractory to current treatments; thus, understanding C/EBP 
regulation of tumor growth potential, could provide a novel therapeutic adjunct for 
aggressive glioblastomas.  
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FIGURE LEGENDS 
 
Figure 1. Expression of C/EBP. (A) Western blot showing C/EBP expression in the 
glioblastoma murine cell line GL261 and in primary cultures of astrocytes in basal 
conditions and after 24 h of lipopolysaccharide (LPS) stimulation. Mouse primary 
astrocytes, were harvested and cultured as previously described (Luna-Medina et al., 
2007). Cultures were stimulated with lipopolysaccharide (10 g/ml, LPS) and cells were 
harvested 24 h later. (B) Expression of C/EBP in control (C1, C2) and C/EBP-
depleted (I4, I5) GL261 pools, as assessed by Western blot analysis. The Westerns 
shown are representative of three different experiments. (C) Expression of C/EBP in 
control (FS) and C/EBP-depleted (FC1) human LN18 cells. (D) Representative 
Western blot showing expression of C/EBPα and C/EBPδ in GL261 (C1 and I4) and 
LN18 (FS and FC1) cells. 
 
Figure 2. Effect of C/EBP depletion on cell viability, proliferation, and 
clonogenicity. (A) C1, I4 and I5 pools were seeded into individual wells of a 96-well 
plate and cultivated for 24 h after which BrdU was added to the culture medium. Cells 
were harvested 16 h after BrdU addition. (B) Cells were grown on glass cover slips for 
24 h and BrdU incorporation was analyzed 16 h after by immunofluorescence using a 
specific anti-BrdU antibody. Bar scale, 50 m. Quantification of the results is shown in 
the right panel. Indicated is the percentage of BrdU
+
 cells. (C) Murine C1 and I4 and 
human FS and FC1 cells were seeded in a 96-well plate and at different times after 
plating cell viability was determined by the MTT assay. (D) Progression through the 
cell cycle was analyzed by PI staining and FACS analysis. Curves modeling the G0/G1, 
S, and G2/M compartment, derived by using the Summit program, are shown. Data are 
representative of three independent experiments. (E) Three weeks after seeding the cells 
in soft agar, 10 randomly selected microscopic fields were counted. Shown are 
representative microphotographs (bar scale 250 m) and quantification. Values in 
panels A, B, C and E represent the means  S.D. of at least three different experiments.  
 
Figure 3. Effects of C/EBP on cell motility and invasion. (A) Murine C1 and I4 and 
human FS and FC1 cells were grown to confluence into a monolayer and a linear 
scratch wound was performed with a plastic pipette tip. Images were taken with a phase 
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contrast microscope at different times after wounding. Representative phase-contrast 
images of the in vitro wound-healing assay are shown. Bar scale, 100 m (B) Cell 
invasion was measured on transwell coated with Matrigel as described in Materials and 
Methods. Values are represented as means  S.D. of three different experiments.  
 
Figure 4. Western blot analysis. Protein lysates from C1, I4, and I5 pools were used 
for western blot analysis using specific antibodies against ATM, chk2, Brca1, and p27, 
as indicated in Materials and Methods. 
 
Figure 5. Effects of C/EBP expression on tumor growth in vivo. Histological and 
immunostaining analysis of tumors induced by GL261-derived pools. (A) T1 magnetic 
resonance imaging (MRI) pictures obtained from mice injected with the GL261-derived 
clones. T1-weighted imaging was performed at 7 Tesla as described in Materials and 
Methods at different times after injection. Cortical images showing the brains of 
representative mice, obtained at 11, 15, and 18 days post-injection are presented. (B) 
Quantitative analysis of total tumor volumes. Values represent the mean  S.D. from 
five different animals. (C) Kaplan-Meier plots and log-rank statistics analysis of overall 
survival reveal that downregulation of C/EBP expression in I4 tumors significantly 
improves survival of tumor-bearing mice compared with their C1 controls (log-rank test 
p = 0.0012). (D) Representative hematoxylin and eosin staining images of the C1- and 
I4-derived tumors. Middle and right panels show higher magnifications of the images 
shown in the two left panels. C1 tumors showed clear blood vessels (arrows) and 
multinuclear giant cells (arrowheads). Scale bars, 100 m (E) Immunocytochemistry 
analysis of tumor sections for PCNA detection. Scale bar, 25 m. 
 
Table I. Effect of C/EBPβ on cancer regulatory gene expression. 
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